About AMITA Health Cancer Institute & Outpatient Center
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Calithera Biosciences, Inc
1
Celgene
1
Eli Lilly and Company
1
Clinical Trials at AMITA Health Cancer Institute & Outpatient Center
During the past decade, AMITA Health Cancer Institute & Outpatient Center conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 2 clinical trials were completed, i.e. on
average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
2014-04-01
2024-07-08
Active, not recruiting
503
Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer
2018-03-19
2020-03-05
Terminated
101
CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma
2018-04-24
2021-07-16
Completed
444
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "AMITA Health Cancer Institute & Outpatient Center"
#1 collaborator was "ARMO BioSciences" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were
collaborators in the rest 1 trials.
Clinical Trials Conditions at AMITA Health Cancer Institute & Outpatient Center
According to Clinical.Site data, the most researched conditions in "AMITA Health Cancer Institute & Outpatient Center" are
"Advanced Renal Cell Carcinoma" (1 trials), "Lymphoma, Non-Hodgkin" (1 trials), "Metastatic Renal Cell Carcinoma" (1 trials) and "Non Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "AMITA Health Cancer Institute & Outpatient Center" in a lesser frequency.
Clinical Trials Intervention Types at AMITA Health Cancer Institute & Outpatient Center
Most popular intervention types in "AMITA Health Cancer Institute & Outpatient Center" are "Drug" (3 trials) and "Biological" (1 trials). Other intervention types were less common.
The name of intervention was led by "CB-839" (1 trials), "Cabozantinib" (1 trials), "Lenalidomide" (1 trials), "Pegilodecakin" (1 trials) and "Pembrolizumab" (1 trials). Other intervention names were less common.
Clinical Trials Genders at AMITA Health Cancer Institute & Outpatient Center
The vast majority of trials in "AMITA Health Cancer Institute & Outpatient Center" are
3 trials for "All" genders.
Clinical Trials Status at AMITA Health Cancer Institute & Outpatient Center
Currently, there are NaN active trials in "AMITA Health Cancer Institute & Outpatient Center".
undefined are not yet recruiting,
undefined are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 1 completed trials in AMITA Health Cancer Institute & Outpatient Center,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in AMITA Health Cancer Institute & Outpatient Center, 0 "Phase 1"
clinical trials were conducted, 2 "Phase 2" clinical
trials and 1 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".